0.7081
Precedente Chiudi:
$0.7872
Aprire:
$0.7361
Volume 24 ore:
154.34K
Relative Volume:
0.62
Capitalizzazione di mercato:
$39.05M
Reddito:
-
Utile/perdita netta:
$-131.52M
Rapporto P/E:
-0.3978
EPS:
-1.78
Flusso di cassa netto:
$-107.56M
1 W Prestazione:
+3.86%
1M Prestazione:
+3.52%
6M Prestazione:
-62.53%
1 anno Prestazione:
-85.00%
Prelude Therapeutics Inc Stock (PRLD) Company Profile
Nome
Prelude Therapeutics Inc
Settore
Industria
Telefono
(302) 467-1280
Indirizzo
175 INNOVATION BOULEVARD, WILMINGTON
Confronta PRLD con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
PRLD
Prelude Therapeutics Inc
|
0.7081 | 39.05M | 0 | -131.52M | -107.56M | -1.78 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-09-19 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
2024-06-20 | Downgrade | Barclays | Equal Weight → Underweight |
2024-03-13 | Iniziato | JMP Securities | Mkt Outperform |
2024-02-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
2023-12-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
2022-11-21 | Downgrade | BofA Securities | Neutral → Underperform |
2022-09-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
2022-07-29 | Iniziato | Jefferies | Buy |
2022-03-15 | Downgrade | BofA Securities | Buy → Neutral |
2022-02-28 | Downgrade | Barclays | Overweight → Equal Weight |
2021-10-08 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
2021-07-27 | Aggiornamento | BofA Securities | Neutral → Buy |
2021-04-26 | Iniziato | H.C. Wainwright | Buy |
2021-03-09 | Iniziato | Barclays | Overweight |
2020-11-20 | Downgrade | BofA Securities | Buy → Neutral |
2020-10-20 | Iniziato | BofA Securities | Buy |
2020-10-20 | Iniziato | Goldman | Neutral |
2020-10-20 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Prelude Therapeutics Inc Borsa (PRLD) Ultime notizie
Charles Schwab Investment Management Inc. Sells 16,049 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World
Prelude Therapeutics reports preclinical profile of first-in-human SMARCA2 degrader - BioWorld MedTech
Prelude Therapeutics Founder Acquires 28% More Stock - Yahoo Finance
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Why Braze Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Benzinga
Prelude Therapeutics stock surges on insider buying - Investing.com
Prelude Therapeutics stock surges on insider buying By Investing.com - Investing.com Australia
Prelude Therapeutics chief chemistry officer acquires $69,250 in stock By Investing.com - Investing.com South Africa
Prelude Therapeutics CEO Vaddi Krishna acquires $467,437 in stock - Investing.com
Prelude Therapeutics chief chemistry officer acquires $69,250 in stock - Investing.com
Prelude Therapeutics CEO Vaddi Krishna acquires $467,437 in stock By Investing.com - Investing.com South Africa
Prelude Therapeutics CEO Vaddi Krishna acquires $14,909 in stock - Investing.com India
Prelude Therapeutics CEO Vaddi Krishna acquires $14,909 in stock By Investing.com - Investing.com Australia
Prelude Therapeutics CEO Krishna Vaddi increases stake with $29,459 stock purchase - Investing.com Australia
Prelude Therapeutics CEO Krishna Vaddi increases stake with $29,459 stock purchase By Investing.com - Investing.com South Africa
Prelude Therapeutics’ SWOT analysis: biotech stock faces mixed outlook amid clinical trials - Investing.com Australia
NiKang Advances CDK2 Degrader with Key Milestone in Cancer Treatment Trial - MyChesCo
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Prelude therapeutics CEO Krishna Vaddi acquires $69,564 in shares By Investing.com - Investing.com South Africa
Prelude therapeutics CEO Krishna Vaddi acquires $69,564 in shares - Investing.com
Prelude Therapeutics Reports 2024 Financial Results and Clinical Pipeline Advancements - MyChesCo
Rhumbline Advisers Purchases 154,826 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World
Prelude Therapeutics Reports 2024 Financial Results - TipRanks
Prelude Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Prelude Therapeutics reports FY24 EPS ($1.68), consensus ($1.77) - TipRanks
Prelude Therapeutics Reports 2024 Financial Results and Updates - TipRanks
Prelude Therapeutics Inc SEC 10-K Report - TradingView
Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025 - GlobeNewswire
PRLDPrelude Therapeutics Inc Latest Stock News & Market Updates - StockTitan
Mineralys Therapeutics to Announce Pivotal Trial Results for Lorundrostat - MyChesCo
Enovis Corporation Announces Participation in Upcoming Investor Conferences - MyChesCo
Prelude Therapeutics to Present at Barclays Global Healthcare Conference - MSN
Aclaris Therapeutics to Participate in Upcoming Healthcare Conferences - MyChesCo
Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference - GlobeNewswire
How Will Prelude's Cancer Pipeline Updates Impact Investors at Upcoming Barclays Conference? - StockTitan
Larimar Therapeutics to Present at Leerink Partners Global Healthcare Conference - MyChesCo
We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully - Yahoo Finance
Prelude Therapeutics Shares Promising Data for CDK9 Inhibitor PRT2527 - MSN
PRLD stock touches 52-week low at $0.79 amid market challenges - Investing.com
Palvella Therapeutics to Present at TD Cowen 45th Annual Healthcare Conference - MyChesCo
Context Therapeutics Grants Stock Options to New Employees - MyChesCo
Windtree Therapeutics Announces Reverse Stock Split to Maintain Nasdaq Compliance - MyChesCo
Mineralys Therapeutics Delivers Financial Update and Advances Pipeline for Lorundrostat - MyChesCo
Prelude Therapeutics (PRLD) to Release Quarterly Earnings on Thursday - Defense World
Delaware weekly roundup: The Eagles’ River; CAFE opens apps; Prelude Therapeutics hires CFO - Technical.ly
Akoya Biosciences Inc (AKYA)’s Day in Review: Closing at 2.34, Down by -4.88 - The Dwinnex
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Mineralys Therapeutics to Announce Q4 and Full-Year 2024 Financial Results - MyChesCo
Prelude Therapeutics Names Bryant Lim As Permanent CFO -February 05, 2025 at 06:35 pm EST - Marketscreener.com
Prelude Therapeutics Appoints Bryant D. Lim as CFO - TipRanks
Prelude Therapeutics Inc Azioni (PRLD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):